PRCT PROCEPT BioRobotics Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Develops and sells AquaBeam and HYDROS robotic systems for minimally invasive urologic surgery focused on benign prostatic hyperplasia (BPH) treatment
• • New emphasis on prostate cancer treatment with ongoing clinical trials including the pivotal WATER IV PCa randomized FDA-approved IDE study
• • Strategic shift toward global expansion and increased efforts in private payor coverage and direct-to-patient marketing beyond urologists
• • Install base growth to 912 robotic systems globally as of Dec 31, 2025, up from prior years, with revenue rising to $308.1 million in 2025
• • Notable investment in AI and machine learning to improve treatment planning and product scalability for future innovation

Risk Factors

• • FDA regulatory risk: ongoing need to comply with FDA requirements for marketing approval and labeling limitations affecting product acceptance
• • Macroeconomic exposure: sales dependent on U.S. hospital and surgeon adoption, limited international presence, market growth constrained by reimbursement variability
• • Supply chain risk: reliance on third-party distributors and suppliers for timely product components and distribution in targeted markets
• • Market disruption threat: competition from established surgical alternatives and emerging robotic or medical technologies impacting surgeon and hospital adoption
• • Financial risk: $52M term loan with restrictive covenants and $286.5M cash on hand with $641.6M accumulated deficit, risking liquidity if covenants breached or capital markets tighten

Management Discussion & Analysis

• • Revenue $308.1M, up 37% YoY from $224.5M; system sales up $15.8M (18%), hand-piece sales up $60.0M (49%)
• • Gross margin 64% vs 61% YoY, cost of sales up 28% to $111.8M driven by higher volume and warranty costs
• • Best segment: hand-pieces with $181.4M revenue, worst: systems at $106.1M; service revenue $20.5M up 61%
• • Operating expenses up 28% to $300.1M; R&D $71.3M (+14%), SG&A $228.8M (+33%) due to sales/marketing expansion
• • Net loss $95.6M vs $91.4M; operating loss $103.9M vs $96.6M; interest expense down 14% to $3.6M; net interest/income up 24% to $12.1M
• • Cash $286.5M, loan outstanding $52.0M; net cash used in operating activities $49.0M; financing inflow $11.2M from stock and ESPP
• • Management expects continued revenue growth from expanding robotic install base and system utilization, investing in R&D and sales infrastructure
• • Risks: reimbursement coverage, cost management, regulatory approval, market competition, and funding needs remain key uncertainties

What are the latest PRCT SEC filings in 2026?

PROCEPT BioRobotics Corp (PRCT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PRCT file its most recent 10-K annual report?

PROCEPT BioRobotics Corp (PRCT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PRCT 10-Q quarterly reports?

PROCEPT BioRobotics Corp (PRCT)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every PRCT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PRCT filed recently?

PROCEPT BioRobotics Corp (PRCT)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PRCT insider trading activity (Form 4)?

SignalX aggregates every PRCT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PRCT file with the SEC?

PROCEPT BioRobotics Corp (PRCT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PRCT filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for PROCEPT BioRobotics Corp (PRCT).

What is PRCT's SEC CIK number?

PROCEPT BioRobotics Corp (PRCT)'s SEC CIK (Central Index Key) number is 1588978. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1588978 to look up all PRCT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PRCT return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from PROCEPT BioRobotics Corp (PRCT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.